Prenetics Global (NASDAQ:PRE) CFO Acquires $116,280.00 in Stock

Prenetics Global Limited (NASDAQ:PRE) CFO Brian Rosin bought 5,100 shares of Prenetics Global stock in a transaction dated Tuesday, August 25th. The stock was purchased at an average price of $22.80 per share, with a total value of $116,280.00. Following the completion of the purchase, the chief financial officer owned 23,100 shares in the company, valued at $526,680. This trade represents a 28.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Prenetics Global Price Performance

Shares of Prenetics Global stock opened at $25.76 on Friday. The business has a 50-day simple moving average of $19.46 and a 200 day simple moving average of $19.08. Prenetics Global Limited has a one year low of $7.41 and a one year high of $26.50. The firm has a market capitalization of $434.57 million, a price-to-earnings ratio of -6.19 and a beta of 0.26.

Prenetics Global (NASDAQ:PRE) last announced its quarterly earnings results on Wednesday, August 19th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.31. The business had revenue of $46.49 million for the quarter, compared to analyst estimates of $49.85 million. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%. On average, sell-side analysts expect that Prenetics Global Limited will post -1.86 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Benchmark upped their price objective on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th. Wall Street Zen upgraded shares of Prenetics Global from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Finally, B. Riley Financial began coverage on Prenetics Global in a research note on Thursday. They set a “buy” rating and a $37.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.80.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in PRE. State of Wyoming bought a new stake in Prenetics Global in the 1st quarter worth about $48,000. Wells Fargo & Company MN purchased a new position in shares of Prenetics Global in the 4th quarter worth approximately $47,000. JPMorgan Chase & Co. purchased a new position in shares of Prenetics Global in the 3rd quarter worth approximately $65,000. Operose Advisors LLC bought a new position in shares of Prenetics Global in the second quarter valued at approximately $129,000. Finally, Stevens Capital Partners grew its holdings in shares of Prenetics Global by 54.6% in the first quarter. Stevens Capital Partners now owns 28,147 shares of the company’s stock valued at $544,000 after acquiring an additional 9,940 shares in the last quarter. 25.01% of the stock is owned by institutional investors.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.